Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Lewis H. Bender
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 16
- Beta
- 3.04
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -13.47
Financials
Net Income
$-3.54MEBITDA
$-3.62MFree Cash Flow
$-2.50MEPS (diluted)
$-1.09Shares Outstanding (diluted)
3.26M+2287.8%Operating Expenses
$3.62MCash & Debt
$8.49MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-11.61M | $-8.56 |
| 2024 | $0.00 | $-16.27M | $-29.25 |
| 2023 | $0.00 | $-10.54M | $-34.50 |
| 2022 | $0.00 | $-7.58M | $-55.50 |
| 2021 | $0.00 | $-7.90M | $-58.00 |
| 2020 | $0.00 | $-5.96M | $-44.25 |
| 2019 | $0.00 | $-5.23M | $-39.50 |
Valuation
INTShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (5)
- Newsseekingalpha.com·15d ago·Positive
Intensity Therapeutics, Inc. (INTS) Q3 2026 Earnings Call Transcript Intensity Therapeutics, Inc. ( INTS ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Joseph Talamo - Chief Financial Officer Conference Call Participants Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Charles Wallace - H.C. Wainwright & Co, LLC, Research Division Ilya Zubkov - Freedom Broker, Research Division James Moll…
View source ↗ - Newsprnewswire.com·17d ago·Positive
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update New patient enrollment activities resumed in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study in the third quarter of 2026 New patient enrollment and treatment resumed in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study in the third quarter of 2026 Cash and cash equivalents of $8.5 million as of September 30, 2026 Conference call be
View source ↗ - Newsprnewswire.com·23d ago·Neutral
…6 to review results and provide a corporate update SHELTON, Conn., Oct. 30, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today announced that it will report financial results for the…
View source ↗ - Newsseekingalpha.com·103d ago·Positive
Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript Intensity Therapeutics, Inc. (INTS) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·103d ago·Positive
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Initiated activities to resume enrollment in a limited number of U.S. sites in the soft tissue sarcoma Phase 3 INVINCIBLE-3 Study by the third quarter of 2026 Patient treatment restarted in the presurgical triple negative breast cancer ("TNBC") Phase 2 INVINCIBLE-4 Study Cash and cash equivalents of $9.5 million as of June 30, 2026 Increased business development activities Conference call begins at
View source ↗
Earnings
Fri, Mar 26(in 4 months)
Consensus estimate $-1.14 per share
Typical surprise -10.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-1.09 vs $-0.99miss
- Tue, Aug 11$-1.11 vs $-0.87miss
- Thu, May 7$-0.96 vs $-1.19beat
- Fri, Mar 27$-1.69 vs $-1.24miss
- Thu, Nov 6$-1.50 vs $-1.58beat
- Thu, Aug 7$-3.25 vs $-0.30miss
Estimates and results for INTS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INTS officers and directors.
No open-market trades in the recent filings. All 58 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
58 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INTS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
